Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5117]
News [14826]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
Nivolumab and ipilimumab for metastatic kidney cancer
Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France
Nivolumab and ipilimumab for metastatic kidney cancer ( Dr Bernard Escudier - Institut Gustave Roussy, Villejuif, France )
11 Sep 2017
Biological insight in new drug combinations
Dr Elena Garralda - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
Biological insight in new drug combinations ( Dr Elena Garralda - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
11 Sep 2017
BRIM8: Vemurafenib in high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
BRIM8: Vemurafenib in high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017
Durvalumab in novel combinations for head and neck cancer
Dr Ezra Cohen - UC San Diego Health, San Diego, USA
Durvalumab in novel combinations for head and neck cancer ( Dr Ezra Cohen - UC San Diego Health, San Diego, USA )
11 Sep 2017
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017
Expert commentary on melanoma immunotherapy latest
Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard
Expert commentary on melanoma immunotherapy latest ( Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard )
11 Sep 2017
Vemurafenib for high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
Vemurafenib for high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017
Dabrafenib plus trametinib for stage III mutant melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Dabrafenib plus trametinib for stage III mutant melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017
Nivolumab vs ipilimumab for high risk melanoma patients
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Nivolumab vs ipilimumab for high risk melanoma patients ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017
ESMO 2017: Prostate cancer highlights
Prof Karim Fizazi, Prof Stephane Oudard, Dr Bertrand Tombal & Prof Maria De...
ESMO 2017: Prostate cancer highlights ( Prof Karim Fizazi, Prof Stephane Oudard, Dr Bertrand Tombal & Prof Maria De Santis )
10 Sep 2017
The METRIC trial of trametinib, five years on
Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany
The METRIC trial of trametinib, five years on ( Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany )
10 Sep 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation